Manipulation of Brain Kynurenines: Glial Targets, Neuronal Effects, and Clinical Opportunities
The DOI matches its Crossref record; 62 of the 62 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Quinolinic Acid: An Endogenous Metabolite That Produces Axon-Sparing Lesions in Rat Brain
Schwarcz, R., Whetsell, W. O., & Mangano, R. M. (1983) · Science · doi:10.1126/science.6849138 · Cited by 1,263
Self-citationNeuropharmacology of quinolinic and kynurenic acids.
Stone, T. W. (1993) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)00441-7 · Cited by 948
Hilmas, C., Pereira, E. F. R., Alkondon, M., Rassoulpour, A., Schwarcz, R., & Albuquerque, E. X. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-19-07463.2001 · Cited by 859
Self-citationPerkins, M. N., & Stone, T. W. (1982) · Brain Research · doi:10.1016/0006-8993(82)91048-4 · Cited by 849
Blood–Brain Barrier Transport of Kynurenines: Implications for Brain Synthesis and Metabolism
Fukui, S., Schwarcz, R., Rapoport, S. I., Takada, Y., & Smith, Q. R. (1991) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1991.tb03460.x · Cited by 761
Self-citationQuinolinic acid: a potent endogenous excitant at amino acid receptors in CNS
Stone, T. W., & Perkins, M. N. (1981) · European Journal of Pharmacology · doi:10.1016/0014-2999(81)90587-2 · Cited by 751 · cited 1×
“In addition, 3-HK and its degradation product, the immediate QUIN bioprecursor 3-hydroxyanthranilic acid, generate superoxide and hydrogen peroxide in a copper-dependent manner and thus promote copper-dependent, oxidative protein damage (Goldstein et al., 2000).”
BackgroundKessler, M., Terramani, T., Lynch, G., & Baudry, M. (1989) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1989.tb01881.x · Cited by 739
Increased cortical kynurenate content in schizophrenia
Schwarcz, R., Rassoulpour, A., Wu, H.-Q., Medoff, D., Tamminga, C. A., & Roberts, R. C. (2001) · Biological Psychiatry · doi:10.1016/s0006-3223(01)01078-2 · Cited by 590
Self-citationKynurenine pathway metabolism in human astrocytes: a paradox for neuronal protection
Guillemin, G. J., Kerr, S. J., Smythe, G. A., Smith, D. G., Kapoor, V., Armati, P. J., Croitoru, J., & Brew, B. J. (2001) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2001.00498.x · Cited by 538
Chronic quinolinic acid lesions in rats closely resemble Huntington's disease
Beal, M., Ferrante, R., Swartz, K., & Kowall, N. (1991) · The Journal of Neuroscience · doi:10.1523/jneurosci.11-06-01649.1991 · Cited by 499
Cited by
Molecular Mechanisms of Depression: Perspectives on New Treatment Strategies
Lang, U. E., & Borgwardt, S. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350094 · Cited by 8,475
Inflammation and Its Discontents: The Role of Cytokines in the Pathophysiology of Major Depression
Miller, A. H., Maletic, V., & Raison, C. L. (2009) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.11.029 · Cited by 3,848
“In addition, based on the differential expression of relevant metabolic enzymes, KYN is preferentially converted to kynurenic acid (KA) in astrocytes and quinolinic acid (QUIN) in microglia (Figure 1)(36).”
InfluentialMammalian nicotinic acetylcholine receptors: from structure to function
Albuquerque, E. X., Pereira, E. F. R., Alkondon, M., & Rogers, S. W. (2009) · Physiological Reviews · doi:10.1152/physrev.00015.2008 · Cited by 1,724
Kynurenines in the mammalian brain: when physiology meets pathology
Schwarcz, R., Bruno, J. P., Muchowski, P. J., & Wu, H.-Q. (2012) · Nature Reviews Neuroscience · doi:10.1038/nrn3257 · Cited by 1,530
Self-citationYing, W. (2008) · Antioxidants & Redox Signaling · doi:10.1089/ars.2007.1672 · Cited by 1,494
“Thus, the kynurenine pathway has been a target for treatment of multiple neurological diseases (206, 249, 255).”
Immune system to brain signaling: Neuropsychopharmacological implications
Capuron, L., & Miller, A. H. (2011) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2011.01.014 · Cited by 1,195
Inflammatory cytokines in depression: neurobiological mechanisms and therapeutic implications
Felger, J. C., & Lotrich, F. E. (2013) · Neuroscience · doi:10.1016/j.neuroscience.2013.04.060 · Cited by 1,180
Korte, S. M., Koolhaas, J. M., Wingfield, J. C., & McEwen, B. S. (2005) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2004.08.009 · Cited by 1,097
Haroon, E., Raison, C. L., & Miller, A. H. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2011.205 · Cited by 1,000
“Nevertheless, these compounds have yet to advance to phase-I–III testing for neuropsychiatric disorders (Stone, 2001; Schwarcz and Pellicciari, 2002).”
BackgroundInfluentialThe neurobiology and control of anxious states
Millan, M. J. (2003) · Progress in Neurobiology · doi:10.1016/s0301-0082(03)00087-x · Cited by 965
Inflammation and immunity in schizophrenia: implications for pathophysiology and treatment
Khandaker, G. M., Cousins, L., Deakin, J., Lennox, B. R., Yolken, R., & Jones, P. B. (2015) · The Lancet Psychiatry · doi:10.1016/s2215-0366(14)00122-9 · Cited by 926
NAD+ in Brain Aging and Neurodegenerative Disorders
Lautrup, S., Sinclair, D. A., Mattson, M. P., & Fang, E. F. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2019.09.001 · Cited by 790
“The ambient levels of these metabolites are determined by different enzymes, which in the brain are preferentially localized in microglia and astrocytes, suggesting necessary glial cell-neuron communication (Schwarcz and Pellicciari, 2002).”
Cytokine, Sickness Behavior, and Depression
Dantzer, R. (2009) · Immunology and Allergy Clinics of North America · doi:10.1016/j.iac.2009.02.002 · Cited by 789
Tolerance, DCs and tryptophan: much ado about IDO
Grohmann, U. (2003) · Trends in Immunology · doi:10.1016/s1471-4906(03)00072-3 · Cited by 766
Maier, S. F., & Watkins, L. R. (2005) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2005.03.021 · Cited by 737
Kynurenine pathway metabolism and the microbiota-gut-brain axis
Kennedy, P. J., Cryan, J. F., Dinan, T. G., & Clarke, G. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.07.002 · Cited by 724
“Similarly, the metabolic fate of kynurenine reaching the CNS is influenced by microglia (See Figure 3 (Schwarcz and Pellicciari, 2002)), whose maturation and function is defective in the absence of a gut microbiota (Erny et al., 2015).”
BackgroundChronic Glutamate Toxicity in Neurodegenerative Diseases—What is the Evidence?
Lewerenz, J., & Maher, P. (2015) · Frontiers in Neuroscience · doi:10.3389/fnins.2015.00469 · Cited by 718
Ravizza, T., Gagliardi, B., Noé, F., Boer, K., Aronica, E., & Vezzani, A. (2008) · Neurobiology of Disease · doi:10.1016/j.nbd.2007.08.012 · Cited by 699
Raison, C. L., Dantzer, R., Kelley, K. W., Lawson, M. A., Woolwine, B. J., Vogt, G., Spivey, J. R., Saito, K., & Miller, A. H. (2010) · Molecular Psychiatry · doi:10.1038/mp.2009.116 · Cited by 630
Inflammation, glutamate, and glia: a trio of trouble in mood disorders
Haroon, E., Miller, A. H., & Sanacora, G. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2016.199 · Cited by 584
Defective tryptophan catabolism underlies inflammation in mouse chronic granulomatous disease
Romani, L., Fallarino, F., De Luca, A., Montagnoli, C., D’Angelo, C., Zelante, T., Vacca, C., Bistoni, F., Fioretti, M. C., Grohmann, U., et al. (2008) · Nature · doi:10.1038/nature06471 · Cited by 535
Tryptophan metabolism in the central nervous system: medical implications
Ruddick, J. P., Evans, A. K., Nutt, D. J., Lightman, S. L., Rook, G. A. W., & Lowry, C. A. (2006) · Expert Reviews in Molecular Medicine · doi:10.1017/s1462399406000068 · Cited by 519
O'Connor, J. C., André, C., Wang, Y., Lawson, M. A., Szegedi, S. S., Lestage, J., Castanon, N., Kelley, K. W., & Dantzer, R. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.5032-08.2009 · Cited by 502
Calder, P. C., Bosco, N., Bourdet-Sicard, R., Capuron, L., Delzenne, N., Doré, J., Franceschi, C., Lehtinen, M. J., Recker, T., Salvioli, S., et al. (2017) · Ageing Research Reviews · doi:10.1016/j.arr.2017.09.001 · Cited by 488
Sas, K., Robotka, H., Toldi, J., & Vécsei, L. (2007) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2007.01.033 · Cited by 463
Inflammation Effects on Motivation and Motor Activity: Role of Dopamine
Felger, J. C., & Treadway, M. T. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2016.143 · Cited by 442
Imaging the Role of Inflammation in Mood and Anxiety-related Disorders
Felger, J. C. (2018) · Current Neuropharmacology · doi:10.2174/1570159x15666171123201142 · Cited by 427
Kynurenines in CNS disease: regulation by inflammatory cytokines.
Campbell, B. M., Charych, E., Lee, A. W., & Möller, T. (2014) · Frontiers in Neuroscience · doi:10.3389/fnins.2014.00012 · Cited by 409
The kynurenine system and immunoregulation
Mándi, Y., & Vécsei, L. (2012) · Journal of Neural Transmission · doi:10.1007/s00702-011-0681-y · Cited by 401
Felger, J. C., & Miller, A. H. (2012) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2012.09.003 · Cited by 391
Role of NAD+ in regulating cellular and metabolic signaling pathways
Amjad, S., Nisar, S., Bhat, A. A., Shah, A. R., Frenneaux, M. P., Fakhro, K., Haris, M., Reddy, R., Patay, Z., Baur, J., et al. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2021.101195 · Cited by 384
Capuron, L., Pagnoni, G., Drake, D. F., Woolwine, B. J., Spivey, J. R., Crowe, R. J., Votaw, J. R., Goodman, M. M., & Miller, A. H. (2012) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2011.2094 · Cited by 382
“Kynurenic acid is synthesized in astrocytes from kynurenine, which is generated from the breakdown of tryptophan by the enzyme indoleamine 2,3-dioxygenase (IDO).(48) Evidence of IDO activation as reflected by decreased peripheral blood tryptophan levels and increased kynurenine levels has been repeatedly associated wi…”
BackgroundWirthgen, E., Hoeflich, A., Rebl, A., & Günther, J. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01957 · Cited by 378
Tryptophan-kynurenine pathway is dysregulated in inflammation and immune activation
Zou, M.-H. (2015) · Frontiers in Bioscience · doi:10.2741/4363 · Cited by 361
Lugo-Huitrón, R., Blanco-Ayala, T., Ugalde-Muñiz, P., Carrillo-Mora, P., Pedraza-Chaverrí, J., Silva-Adaya, D., Maldonado, P. D., Torres, I., Pinzón, E., Ortiz-Islas, E., et al. (2011) · Neurotoxicology and Teratology · doi:10.1016/j.ntt.2011.07.002 · Cited by 346
An expanding range of targets for kynurenine metabolites of tryptophan
Stone, T. W., Stoy, N., & Darlington, L. G. (2013) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2012.09.006 · Cited by 344
Depression and immunity: A role for T cells?
Miller, A. H. (2010) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2009.09.009 · Cited by 337
Giorgini, F., Guidetti, P., Nguyen, Q., Bennett, S. C., & Muchowski, P. J. (2005) · Nature Genetics · doi:10.1038/ng1542 · Cited by 328
Bay-Richter, C., Linderholm, K. R., Lim, C. K., Samuelsson, M., Träskman-Bendz, L., Guillemin, G. J., Erhardt, S., & Brundin, L. (2015) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2014.07.012 · Cited by 304
“KYNA is known to have neuroprotective and anticonvulsant properties (Foster et al., 1984; Schwarcz and Pellicciari, 2002).”
BackgroundThe Role of Immune System in Schizophrenia
Muller, N., & J. Schwarz, M. (2010) · Current Immunology Reviews · doi:10.2174/157339510791823673 · Cited by 291
The kynurenine pathway of tryptophan degradation as a drug target
Schwarcz, R. (2004) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2003.10.006 · Cited by 265
Self-citationShelton, R. C., & Miller, A. H. (2010) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2010.04.004 · Cited by 261
Neostriatal and cortical quinolinate levels are increased in early grade Huntington's disease
GUIDETTI, P., LUTHICARTER, R., AUGOOD, S., & SCHWARCZ, R. (2004) · Neurobiology of Disease · doi:10.1016/j.nbd.2004.07.006 · Cited by 260
Self-citationPlasma kynurenine levels are elevated in suicide attempters with major depressive disorder
Sublette, M. E., Galfalvy, H. C., Fuchs, D., Lapidus, M., Grunebaum, M. F., Oquendo, M. A., John Mann, J., & Postolache, T. T. (2011) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2011.05.002 · Cited by 250
“Thus KYN metabolites can influence glutamatergic (Muller and Schwarz, 2007), dopaminergic (Amori, 2009; Poeggeler, 2007), and cholinergic (Schwarcz and Pellicciari, 2002) tone.”
BackgroundConsensus paper of the WFSBP Task Force on Biological Markers: Biological Markers in Depression
Mössner, R., Mikova, O., Koutsilieri, E., Saoud, M., Ehlis, A.-C., Müller, N., Fallgatter, A. J., & Riederer, P. (2007) · The World Journal of Biological Psychiatry · doi:10.1080/15622970701263303 · Cited by 254
Impaired Kynurenine Pathway Metabolism in The Prefrontal Cortex of Individuals With Schizophrenia
Sathyasaikumar, K. V., Stachowski, E. K., Wonodi, I., Roberts, R. C., Rassoulpour, A., McMahon, R. P., & Schwarcz, R. (2011) · Schizophrenia Bulletin · doi:10.1093/schbul/sbq112 · Cited by 253
Self-citationToxoplasma gondii Infection and Self-directed Violence in Mothers
Pedersen, M. G., Mortensen, P. B., Norgaard-Pedersen, B., & Postolache, T. T. (2012) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2012.668 · Cited by 206
Inflammatory cytokine-associated depression
Lotrich, F. E. (2015) · Brain Research · doi:10.1016/j.brainres.2014.06.032 · Cited by 183
Microglial activation in the pathogenesis of Huntington's disease
Yang, H.-M., Yang, S., Huang, S.-S., Tang, B.-S., & Guo, J.-F. (2017) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2017.00193 · Cited by 151
“Taking into account of the studies above, drugs that can inhibit KP enzymes may offer potential therapeutic approaches by preventing neurotoxicity caused by downstream toxic products (Schwarcz and Pellicciari, 2002).”
BackgroundHaroon, E., & Miller, A. H. (2016) · Current Topics in Behavioral Neurosciences · doi:10.1007/7854_2016_40 · Cited by 153
Mongan, D., Ramesar, M., Föcking, M., Cannon, M., & Cotter, D. (2020) · Early Intervention in Psychiatry · doi:10.1111/eip.12859 · Cited by 123
Microbiota, immunoregulatory old friends and psychiatric disorders
Rook, G. A. W., Raison, C. L., & Lowry, C. A. (2014) · Advances in Experimental Medicine and Biology · doi:10.1007/978-1-4939-0897-4_15 · Cited by 117
Potential roles of zinc in the pathophysiology and treatment of major depressive disorder
Swardfager, W., Herrmann, N., McIntyre, R. S., Mazereeuw, G., Goldberger, K., Cha, D. S., Schwartz, Y., & Lanctôt, K. L. (2013) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2013.03.018 · Cited by 116
The role of dopamine in inflammation-associated depression: mechanisms and therapeutic implications
Felger, J. C. (2016) · Current Topics in Behavioral Neurosciences · doi:10.1007/7854_2016_13 · Cited by 115
Kynurenine pathway in psychosis: evidence of increased tryptophan degradation
Barry, S., Clarke, G., Scully, P., & Dinan, T. (2009) · Journal of Psychopharmacology · doi:10.1177/0269881108089583 · Cited by 96
Role of Inflammation in Depression: Implications for Phenomenology, Pathophysiology and Treatment
Raison, C. L., & Miller, A. H. (2013) · Modern Trends in Psychiatry · doi:10.1159/000343966 · Cited by 88
Endonuclease G mediates α‐synuclein cytotoxicity during Parkinson's disease
Büttner, S., Habernig, L., Broeskamp, F., Ruli, D., Vögtle, F. N., Vlachos, M., Macchi, F., Küttner, V., Carmona‐Gutierrez, D., Eisenberg, T., et al. (2013) · The EMBO Journal · doi:10.1038/emboj.2013.228 · Cited by 87
Smith, A. K., Simon, J. S., Gustafson, E. L., Noviello, S., Cubells, J. F., Epstein, M. P., Devlin, D. J., Qiu, P., Albrecht, J. K., Brass, C. A., et al. (2012) · Molecular Psychiatry · doi:10.1038/mp.2011.67 · Cited by 84
Kynurenic Acid Levels are Increased in the CSF of Alzheimer’s Disease Patients
González-Sánchez, M., Jiménez, J., Narváez, A., Antequera, D., Llamas-Velasco, S., Martín, A. H.-S., Molina Arjona, J. A., López de Munain, A., Lleó Bisa, A., Marco, M.-P., et al. (2020) · Biomolecules · doi:10.3390/biom10040571 · Cited by 84
“Therefore, any imbalance in the KP and subsequently in the production of TRP metabolites may cause neuronal damage, giving rise to multiple physiological and neurological impairments [16,17].”
BackgroundInflammatory Biomarkers in Depression: An Opportunity for Novel Therapeutic Interventions
Li, M., Soczynska, J. K., & Kennedy, S. H. (2011) · Current Psychiatry Reports · doi:10.1007/s11920-011-0210-6 · Cited by 53
“Animal studies indicate that cytokines alter serotonin (5HT) turnover in multiple brain regions [16], downregulate 5HT1A receptors [17], and reduce 5HT availability through activation of indoleamine 2,3-dioxygenase (IDO), the enzyme that breaks down the 5HT precursor tryptophan into kynurenine (KYN) [18].”
BackgroundKynurenine Pathway of Tryptophan Metabolism in Migraine and Functional Gastrointestinal Disorders
Fila, M., Chojnacki, J., Pawlowska, E., Szczepanska, J., Chojnacki, C., & Blasiak, J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221810134 · Cited by 50
“The 3-HK can be neurotoxic through the induction of oxidative stress, and QUIN may be excitotoxic as an NMDA receptor agonist [77,78].”
BackgroundZhou, Y., Liu, W., Zheng, W., Wang, C., Zhan, Y., Lan, X., Zhang, B., Zhang, C., & Ning, Y. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.01.001 · Cited by 23
Inflammatory markers and incident depression: evidence in a population-based prospective study
Shi, R., Gwee, X., Chua, D. Q., Tan, C. T., Yap, K. B., Larbi, A., Lu, Y., & Ng, T. P. (2022) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2022.105806 · Cited by 23
Vandresen-Filho, S., Severino, P. C., Constantino, L. C., Martins, W. C., Molz, S., Dal-Cim, T., Bertoldo, D. B., Silva, F. R. M. B., & Tasca, C. I. (2015) · Neurotoxicity Research · doi:10.1007/s12640-014-9496-6 · Cited by 17
Metadata
- Authors
- Schwarcz, R., & Pellicciari, R.
- Venue
- The Journal of Pharmacology and Experimental Therapeutics
- Publisher
- Elsevier BV
- Published
- 2002-01
- Volume
- 303
- Issue
- 1
- Pages
- 1-10
- ISSN
- 0022-3565 (ISSN-L)
- OpenAlex
- W2120276500
- Cited by
- 556
- References
- 62
- FWCI
- 7.23
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.